EMEA-001613-PIP03-21-M01 - paediatric investigation plan

tezepelumab
PIP Human

Key facts

Invented name
Tezspire
Active substance
tezepelumab
Therapeutic area
Gastrointestinal disorders
Decision number
P/0281/2024
PIP number
EMEA-001613-PIP03-21-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of eosinophilic esophagitis
Route(s) of administration
Subcutaneous use
Contact for public enquiries

AstraZeneca AB
Email: paediatrics@astrazeneca.com
Tel.  +46 855326000

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
No

Decision

Share this page